Wednesday, 4D Molecular Therapeutics, Inc.(NASDAQ:FDMT) unveiled interim 24-week data from the Population Extension cohort of its PRISM Phase 2 Clinical Trial. The trial evaluates intravitreal 4D ...

A newly discovered way for oxygen to form in carbon-dioxide-rich atmospheres of exoplanets could help guide scientists' search for alien life.

Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 monthsAcceptable safety profile across all cohorts ...

Building on these results, they've now used advanced molecular dynamics simulations to propose a new hypothesis: that between the nonmetal and metal phases, there exists a third phase ...

4D Molecular Therapeutics has initiated its first Phase 3 trial for 4D-150 in wet AMD and expanded its clinical pipeline.

Oxygen had been previously observed on the nightside of Venus, but this marks the first time researchers have detected it in the day-lit regions as well. The researchers suspect that the molecular ...

“Dosing the first patient in the Phase 1 clinical trial of 4D-110 marks the first of three Therapeutic Vector Evolution pipeline candidates expected to enter the clinic in 2020,” said David ...

Vivasc Therapeutics Inc. Receives Its Second NIH Phase I STTR Grant With the Goal of Reversing the Molecular Causes of Heart Failure ...

In the era of molecular therapy of chronic myelogenous leukemia (CML) applying BCR-ABL tyrosine kinase inhibitors, the usefulness of molecular end points, in particular, quantitative polymerase chain ...

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study The following represents disclosure information ...